PedAM
Pediatric Disease Annotations & Medicines
| Disease | thalassemia |
| Phenotype | |iron overload |
| Sentences | 80 |
| PubMedID- 23516830 | In this study production levels of interleukins (il)-12 and il-13 were measured by commercial elisa in culture supernatants of mitogen-stimulated peripheral blood mononuclear cells-from 30 non-splenectomized beta-thalassaemia cases with iron overload and 20 age- and sex-matched healthy individuals. |
| PubMedID- 22665732 | Most of the endocrine complications in thalassaemia are attributable to iron overload which may be the result of economic circumstances (expense of the chelation therapy), late onset of chelation therapy or poor compliance with the iron chelation therapy. |
| PubMedID- 19756955 | Hepcidin mutation in a beta-thalassemia major patient with persistent severe iron overload despite chelation therapy. |
| PubMedID- 23966805 | Although it was being used in other countries, deferiprone received fda approval only in october 2011 for treatment of patients with transfusional iron overload due to thalassemia syndromes who were not adequately chelated with other agents. |
| PubMedID- 25616857 | A number of studies have reported heterogeneity of iron distribution in subjects with iron overload due to thalassemia [3-5]. |
| PubMedID- 22089614 | In southeast asia, both thalassaemias with iron overload and patients with iron deficiency co-exist in the same population. |
| PubMedID- 24555000 | [1] transfusional hemosiderosis in major thalassemia patients leads to iron overload and then iron deposition in some organs. |
| PubMedID- 22900514 | The complete treatment of transfusional iron overload in thalassaemia using the deferiprone (l1) and deferoxamine combination is a paradigm to be followed in the treatment of many other metal toxicity conditions. |
| PubMedID- 25820920 | The deferiprone and deferasirox combination is efficacious in iron overloaded patients with beta-thalassemia major: a prospective, single center, open-label study. |
| PubMedID- 24040004 | iron overload in patients with thalassemia results from both excessive iron absorption and transfusion. |
| PubMedID- 25850001 | Furthermore, a pilot trial investigating the effect of amlodipine (a ccb) on iron overload in patients with thalassemia major reported that it can serve as a complementary treatment to standard chelation regimens and may improve the efficacy of iron removal in the heart without the burden of significant side effects [23]. |
| PubMedID- 23228075 | Recently it has been used to detect myocardial dysfunction related to iron overload in patients with beta-thalassemia [66]. |
| PubMedID- 25822525 | Tnf-α and il-10 were found to be elevated in iron overloaded patients with thalassemia major [30]. |
| PubMedID- 23600689 | Assessment and management of iron overload in beta-thalassaemia major patients during the 21st century: a real-life experience from the italian webthal project. |
| PubMedID- 23834310 | Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with beta-thalassemia major and severe iron burden. |
| PubMedID- 23026844 | Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a uk perspective. |
| PubMedID- 23426199 | iron overload in beta-thalassemia intermedia: an emerging concern. |
| PubMedID- 25671931 | Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major. |
| PubMedID- 21733147 | Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. |
| PubMedID- 25878400 | [47] recently reviewed the iron chelating activity of african walnut and wheat grass extracts as to their potential for natural iron removal agents for iron overload associated with thalassemia, which is currently typically treated clinically with desferal. |
| PubMedID- 23460118 | However, in the case of patient with primary myelofibrosis the magnetic anisotropy energy barrier differed from that in normal case and, probably, the iron core size was supposed to be slightly larger than that in both normal spleen tissue and normal human liver ferritin in contrast to well-known data for iron overload in patients with thalassemia accompanied by the iron-core size increase. |
| PubMedID- 26114738 | Efficacy of deferasirox (exjade(r)) in modulation of iron overload in patients with beta-thalassemia intermedia. |
| PubMedID- 24646011 | Moreover, chronic conditions associated with ineffective erythropoiesis, such as non-transfusion-dependent thalassaemia (ntdt), may lead to iron overload through increased gut absorption of iron starting in childhood. |
| PubMedID- 21808992 | Taken together, iron overload in patients with beta-thalassaemia major may potentially result in arterial dysfunction via its effects on the quantity and function of epcs. |
| PubMedID- 21531154 | Combined chelation treatment may be a better approach for transfusion-dependent thalassemia major patients with iron overload complications because of increased efficacy. |
| PubMedID- 23028894 | Given the well documented impaired exercise capacity of thalassaemia patients with significant iron overload [10], [11], a submaximal exercise testing protocol was adopted. |
| PubMedID- 26205801 | Objectives: 'the aim of this work was to compare the efficacy of different iron chelating agents' in the treatment of ' iron overload in children with beta thalassemia major'. |
| PubMedID- 23963793 | Authors' conclusions: desferrioxamine is the recommended first-line therapy for iron overload in people with thalassaemia major and deferiprone or deferasirox are indicated for treating iron overload when desferrioxamine is contraindicated or inadequate. |
| PubMedID- 25801075 | Methods and materials: in this quasi-experimental study, serum ferritin levels were evaluated in 32 beta-thalassemia major patients with severe iron overload before and after receiving combined deferasirox (30-40 mg kg(-1) day(-1) ) and deferoxamine (40-50 mg kg(-1) day(-1) ) 2 days a week. |
| PubMedID- 24847266 | iron overload in patients with beta-thalassemia major lead to alterations in the arterial structures and in the thickness of the carotid arteries (cheung et al., 2002; tantawy et al., 2009). |
Page: 1 2